MyMedLab Creates Liver Panel in Response to Acetaminophen Warnings

Share Article

FDA Warning has many consumers concerned about exposure to excessive levels of a common drug

Convenient and affordable access to information allows consumers to make informed choices that can have dramatic effects on their health. Our Acetaminophen Liver Panel is a simple way for consumers concerned about the dangers addressed by the FDA to receive this valuable health information

MyMedLab, Inc. today announced the creation of a new Acetaminophen Liver Panel in response to recent FDA concerns regarding the overuse of the common pain medication Acetaminophen. The FDA issues their advisory in response to the danger of continued overuse of Acetaminophen, in both OTC formulations as well as in combination with other medications. While very common and widely available, Acetaminophen in high doses and/or prolonged daily use, can lead to liver damage and death. Because of the easy access and OTC nature of Acetaminophen, many consumers are unaware of the health risks associated with its use.

"Convenient and affordable access to information allows consumers to make informed choices that can have dramatic effects on their health. Our Acetaminophen Liver Panel is a simple way for consumers concerned about the dangers addressed by the FDA to receive this valuable health information", explains CEO David Clymer. "Creating a specific panel of tests that are immediately available to the consumer is an example of the MyMedLab commitment to common sense health care solutions." says Clymer.

The MyMedLab Acetaminophen Liver Panel includes 8 specific tests providing a broad view of overall liver health, including the 3 major enzymes ALT, AST and GGT. This and other tests can be purchased by the consumer, at a fraction of the normal cost, and includes local collection at over 2000 locations without an appointment. The entire testing process from buying the test to receiving the confidential results is reviewed by a licensed physician in their state and can be completed in as little as 24 hours.

Additional advisory information is expected to become available following a recent joint meeting of the Drug Safety and Risk Management Advisory Committee, the Nonprescription Drug Advisory Committee, and the Anesthetic and Life Support Drugs Advisory Committee that met on June 29 and 30, 2009.

About MyMedLab. MyMedLab is a privately held company with the primary mission of empowering consumers to make informed health care choices. As a leading provider of direct-to-consumer (DTC) laboratory testing services, MyMedLab has developed a unique suite of software applications and professional networks that enable the ordering, processing, and reporting of test results directly to consumers. This innovative set of services includes access to wellness tests organized by organ and disease profiles, physician oversight of test ordering, educational laboratory content, and results reporting through the web-based platform. In addition to the direct to consumer channel, MyMedLab also offers their software as a subscription service to physician offices or provider organizations developing community outreach programs that incorporate DTC services. For additional information, please see http://www.mymedlab.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

DAVID CLYMER
MyMedLab
417-434-1001
Email >
Visit website